Drug exposure during breastfeeding: a descriptive population- based cohort study with SIDIAP database

Drug exposure during breastfeeding: a descriptive population- based cohort study with SIDIAP database | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article Drug exposure during breastfeeding: a descriptive population- based cohort study with SIDIAP database Maria Giner-Soriano, Guim Arbona Ricart, Àurea Cartanyà-Hueso, and 4 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-7091470/v1 This work is licensed under a CC BY 4.0 License Status: Published Journal Publication published 24 Dec, 2025 Read the published version in International Breastfeeding Journal → Version 1 posted 9 You are reading this latest preprint version Abstract Background There is a gap in the knowledge of drug exposure during breastfeeding due to exclusion of lactating individuals from studies. It makes difficult to fully understand the implication of drug use while breastfeeding and potential risks to newborns. Breastfeeding information in the Electronic Health Records (EHR) may help us to increase this evidence. We aimed to describe drug exposure during breastfeeding in mothers of a cohort of mother-infant linked pairs in Catalonia, Spain. Methods We conducted a descriptive population-based cohort study including mother-infant linked pairs of infants born during 2010–2022. The data source was the Information System for Research in Primary Care (SIDIAP), including sociodemographic characteristics, comorbidities, prescribed and reimbursed drugs, and lactation registers. Lactation is registered in the infants’ EHR. We analyzed drug exposure from delivery up to 2, 4, 6 and 12 months afterwards. We described categorical variables by absolute frequency and percentage and continuous variables by mean and standard deviation. Results We included 176,324 mother-infant pairs with lactation registers during the first year after birth. Breastfed infants decreased during the first year to 64,225 (36.4%). Drug exposure varied from 76,064 (43.1% of the lactating mothers) from delivery up to month 2, to 32,475 (21.9%), 17,396 (17.6%) and 20,433 (31.8%) at up to months 4, 6 and 12, respectively. The most dispensed drugs were iron (25%), folic acid (15.5%) and analgesics (17.8%). Paracetamol was the most frequent analgesic (89.7%), amoxicillin and fosfomycin were the most frequent antibiotics (92.4% and 89.4%), or ibuprofen the most frequent non-steroidal anti-inflammatory drug (75.6%). Conclusions The number of lactating and drug-exposed mothers decreased over time. Iron and supplements were the most used drugs, mainly during the first two months, probably due to continuation since pregnancy or post-partum anemia. Analgesics and penicillins were also frequent, which might be used for common acute conditions. Our main limitation is the potential underreporting of drug exposure due to lack of information on over-the-counter drugs. Trial registration “Drug use in pregnant and breastfeeding women. Outcomes in the health of the women and the offspring”, EUPAS47450, registered at the HMA-EMA Catalogues of real-world data sources and studies: https://catalogues.ema.europa.eu/node/3222/administrative-details Breastfeeding Lactation Drug exposure Electronic Health Records Mother-child relation Pharmacoepidemiology Prevalence Figures Figure 1 Figure 2 Figure 3 Background Pregnancy and breastfeeding are physiological process in females’ fertility life where there is a lack of comprehensive data on drug safety due to the exclusion of pregnant and lactating individuals from clinical trials and other studies for ethical reasons and due to the generalised under-investigation in women’s health. 1 – 4 In 2015, the United States Food and Drug Administration (FDA) implemented the Pregnancy and Lactation Labelling Rule to assist in the prescription decision making process during pregnancy and lactation requiring a narrative description of the risks and clinical considerations of drugs differentiated into three sections: gestation (including childbirth), lactation and, reproductive potential in men and women. 5 , 6 The European Medicines Agency establishes in its Good Practice Guide on Pharmacovigilance for specific populations – pregnant and breastfeeding women – that it is necessary to carry out post authorization observational safety studies on those drugs that cannot be discontinued during pregnancy, drugs to treat gestational/lactational diseases or drugs that in preclinical studies have shown some type of risk for the offspring. 7 Despite the warnings on the use of some drugs in pregnancy or breastfeeding, it is not always advisable to discontinue some chronic drug treatments due to an increased risk of disease complications in the mother or offspring. 4 , 8 In Spain, the tool e-lactancia.org is widely used by healthcare professionals to search for information on drug exposure during breastfeeding and as providers seen it useful during the prescription process. 9 It classifies the drugs in one of four categories, according to their compatibility to be administered while breastfeeding. 10 The electronic health records in Catalonia (ECAP) 11 include the PREFASEG (Safe Pharmacological Prescription) tool in the prescription software, which alerts on drug-drug interactions, allergies, duplicated treatments and contraindications, and includes alerts related to pregnancy and lactation. 12 However, lactating individuals and their healthcare professionals often lack data to support their decisions on medication use. This gap in knowledge makes it challenging to fully understand the implication of drug use while breastfeeding and potential risks to newborns, as some drugs may pass into breast milk. 8 Breastfeeding information stored in the electronic health records (EHR) can be used for pharmacoepidemiology research. 13 , 14 Some population-based studies have been conducted to fill in this gap, as healthcare databases offer numerous advantages when studying the safety of drug use during lactation. 15 – 17 As mother-infant linked information is available in our database, it is possible to study drug exposure in mothers during breastfeeding. For this reason, we aimed to describe drug exposure during breastfeeding in mothers of a cohort of mother-infant linked pairs in Catalonia, Spain. Methods Design and study populations Descriptive observational study using a population-based cohort of mother-infant linked pairs. The populations included mothers and infants with linked EHR. Study period We analyzed the information available for those mother-infant linked pairs for infants born from January 2010 to December 2022. Data source The study data source was SIDIAP, which captures clinical information of 5.8 million people from Catalonia, Spain. 18 , 19 SIDIAP database is pseudonymized and contains information from different data sources: 1) EHR in primary health care of the Catalan Health Institute (approximately attending 75% of the Catalan population); including sociodemographic characteristics, comorbidities registered as International Classification of Diseases, 10th revision, Clinical Modification (ICD­10-CM) codes (Supplementary Table S1 ), 20 specialist referrals, clinical parameters, toxic habits, sickness leave, date of death, laboratory test, pediatric visits, 21 and drug prescriptions issued in Primary Health Care, registered as Anatomical Therapeutic Chemical (ATC) classification system codes (Supplementary Table S2). 22 2) Sexual and reproductive healthcare (ASSIR) records, which is the EHR module used by gynecologists and midwives to register variables related with the sexual and reproductive health of women and follow-up of pregnancies. 3) Pharmacy invoice data corresponding to the Primary Care drug prescriptions, classified according to the ATC classification. 24 SIDIAP has established an algorithm that links mothers with their offspring. 23 This algorithm was applied to identify the mother-infant pairs of interest for this study. We included all children born in 2010–2022 linked to their mothers with lactation registers in their EHR. Variables Variables were retrieved from the mother-infant pairs as follows: Infants’ variables ; sociodemographic variables (age and sex) and registers of lactation in the EHR during the first 12 months after birth. Maternal variables ; sociodemographic variables (age and MEDEA socioeconomic index 24 ), comorbidities up to delivery date, pregnancy follow-up variables (e.g. gestational week, delivery procedures), drug exposure during the first year of breastfeeding. We analyzed the drug exposure from delivery up to four time-cuts after birth while lactating: in the first 2 months, from months 2 to 4, from months 4 and 6 and from 6 up to 12 months. Statistical analysis We described maternal and infant characteristics by absolute frequency and percentage categorical variables and by mean and standard deviation, and median and interquartile range continuous variables. In addition, we calculated the prevalences of drug use during breastfeeding, during first two months, between the third and fourth months, between fifth and sixth months, between seventh and twelfth months and during the first year. Drugs used by at least 0.5% of mothers at any time points were described. Results We identified 176,324 mother-infant pairs with breastfeeding registers during the first year after birth in our study period (Figure 1). Infants receiving breast milk decreased progressively through the first year of life, from 176,324 to 148,413 (84.2%) during months 2 to 4, 98,635 (55.9%) during months 4 to 6, and 64,225 (36.4%) from months 6 to 12. The mean duration of the breastfeeding was 6.2 months (SD 3.8) and the median, 6.0 (IQR 3.0-9.0). The distribution of infants and their breastfeeding records from 2010 to 2022 is shown in Figure 2. The proportion of breastfed infants for up to 2 months increased approximately from 2017 to 2022, while the proportion of infants receiving breastfeeding up to 4 months decreased. The proportions for the other two time-cuts are stable. The proportions in 2022 do not follow the same pattern due to the censoring of the end of study period. Baseline mothers’ characteristics are described in Table 1. They had a mean age of 32.3 years (SD 5.5), their MEDEA socioeconomic index was rural for 25,765 of them (17.6%), and 65,823 (45.1%) lived in the least deprived urban areas. Smoking habit was registered during pregnancy or the previous 12 months only for 33,079 (18.8%) of the mothers, being 5,814 (17.6%) current smokers. Body mass index was registered during pregnancy or the previous 12 months only for 39,689 (22.5%) of the mothers and 19,003 of them (47.9%) overweight or obese. More than half of the mothers had at least one comorbidity (N= 96,635, 54.8%), psychiatric diagnoses were the most frequent ones (24.9%), followed by obesity (9.4%). More than half of the mothers were exposed to drugs 96,094 (54.5%) during the first year after delivery. Mothers exposed to drugs varied from 76,064 (43.1% of the lactating mothers) from delivery up to month 2, to 32,475 (21.9%), 17,396 (17.6%) and 20,433 (31.8%) at up to months 4, 6 and 12, respectively (Figure 3). Table 2 includes the most dispensed pharmacological groups over the 12 months analyzed in at least 0.5% of the mothers. We also describe the most frequent drug of each group. Iron (25%), folic acid (15.5%) and analgesics (17.7%) were the most frequently used drugs by breastfeeding mothers. Paracetamol was the most frequent analgesic (90.2% of all analgesics), amoxicillin and fosfomycin were the most frequent antibiotics (90% and 89.4% of their corresponding groups), or ibuprofen the most frequent non-steroidal anti-inflammatory drug (NSAID, 75.6%). Figure 3 includes the 10 most frequent pharmacological groups dispensed at the four time-cuts analyzed. The most common ones at month 2 were iron (23.2%), folic acid (14.7%), vitamin B12 (12%) and analgesics (10.6%). All pharmacological groups decreased their exposure in subsequent time-cuts. In the Supplementary Table S3 we have included all pharmacological groups dispensed in at least 0.5% of the mothers in any of the four time-cuts studied. Discussion We studied 176,324 mother-infant pairs with lactation registries during the 12 months after birth to analyze the drug exposure of the mothers during the lactation period. The number of breastfed infants decreased over time after birth and the lactating mothers exposed to drugs also decreased up to 6 months, to further increase from months 7 to 12. As expected, the number of infants receiving breast milk progressively diminished during the first year of life, with a mean duration of 6.2 months, as they usually start food other than milk at month 6, 21 , 25 and the mandatory duration of maternity leave in Spain is 16 weeks, 26 hindering the maintenance of exclusive breastfeeding even before the World Health Organization recommendations. 25 In fact, some studies in Spain have reported breastfeeding duration in different cohorts and they also found decrease in the number of infants receiving breast milk, stopping before guidelines recommendations. 27 – 30 The number of lactating mothers exposed to drugs decreased from month 2 to months 4 and 6, but slightly increased at month 12. The decrease may be caused by the mother’s awareness of the potential harms of drug exposure to lactating infants, 31 whereas the increase from months 6 to 12 could be caused by the reduction of numbers of breastfeeding sessions over time as the infant grows, 28 , 30 , 32 thus the mothers get exposed to drugs more frequently. Regarding drug exposure, iron and vitamin supplements were the most used drugs by breastfeeding women, mainly during the first 2 months after birth, probably due to continuation since pregnancy or due to postpartum anemia in the case of iron, which is a relatively frequent condition. 33 – 36 Penicillins were also frequently dispensed during breastfeeding, which might be used for common acute conditions, for instance, mastitis. 10 , 37 Although it is not the recommended antibiotic for mastitis, 38 – 40 amoxicillin was the most widely used, which is safe to treat other common infections during lactation, such as respiratory infections. 10 Other frequent antibiotic in our analysis included fosfomycin, which is indicated for urinary tract infections, and it is reported to be safe both during pregnancy and breastfeeding. 4 , 10 Analgesics, mainly paracetamol, and NSAID, mainly ibuprofen, were also commonly used and increased from month 6 to 12, probably related to the decrease of breast milk feedings over time. Both ibuprofen and paracetamol are safe analgesic during breastfeeding. 10 Also some drugs for prevalent respiratory conditions were frequently used, such as inhalers or antihistamines, most being compatible with breastfeeding. 4 , 10 Information on drug exposure during pregnancy from different populations is available in the literature, whereas there is not as much information concerning breastfeeding. Palmsten et al. is one of the most recent studies reporting drug exposure in lactating mothers at 2, 4 and 6 months after birth, including 4,198 infants receiving breastmilk and born from May 2018 to June 2019, collected during the routine child health care visits. The most common drug exposures included progestin contraceptives (19.1%), or selective-serotonin reuptake inhibitors (SSRI) antidepressants (8.8%). As in our study, they also reported some antibacterials and NSAID among the most frequent ones. 15 A birth cohort in Brazil included 3,988 lactating women in 2015 and studied drug exposure at delivery and after 3 and 12 months while breastfeeding. They reported central nervous system medications as the most frequently used (29%), and others similar to those found in our study, such as paracetamol or ferrous sulphate. 41 Malm et al. conducted a register-based study in Finland in 1999 in pregnant and lactating population, reporting decline throughout the pregnancy period and increase again during lactation for: systemic antimycotics, NSAID, antipsychotics, anxiolytics, hypnotics, sedatives, antidepressants and antihistamines. Antiepileptics use remained stable throughout pregnancy and lactation. 17 De Waard et al. conducted a survey in 292 Dutch women to study prevalence of drug use in pregnancy and lactation. Frequent medications included analgesics, vitamins, iron and laxatives. 42 Campbell et al. extracted data from calls to a teratogen information service in Utah, USA (MotherToBaby Utah), during 2009–2012. They identified 46,031 drug exposures, concerning breastfeeding 34.2% of them, but the drugs reported did not distinguish between pregnancy or lactation exposures. 43 Some studies focused on antidepressants during pregnancy or at delivery. The Australian cohort of Legget et al. included 32,662 women delivering in 2001–2008 and obtained data from hospital EHR for those breastfeeding at discharge after birth. 16 They studied exposure to antidepressants, reported in 1.8% of the cohort, compared with unexposed with and without psychiatric illness. 16 Gorman et al. also studied SSRI exposure at the time of delivery for 446 mothers in California and found that those exposed were significantly less likely to initiate breastfeeding. 44 Also Jordan et al. found that pregnant women exposed to antidepressants breastfed less frequently than non-exposed. 45 In summary, apart from Palmsten et al. and Lutz et al., few cohort studies have analyzed drug exposure during lactation. Both studies reported mothers’ drug use at different time-cuts during the lactation period, finding similar frequent drugs to those reported in our study. In our setting, breastfeeding is routinely recorded in the infants’ EHR, making it necessary to use mother-infant linked information to study mothers’ drug exposure. The potential limitations of using this approach should be considered. The first limitation could be the misclassification of lactation status, which is collected during the routine visits during childhood. 21 Thus, a second limitation in our data source could be the inability to distinguish between exclusive breastfeeding and mixed feeding (breast milk and other food) in the lactation registries. A third limitation is caused by the information available on the drug dispensing registries in our database, which might have errors incurring in a potential misclassification of start and end of exposure. Another limitation is the potential underreporting of drug exposure due to lack of information on over the counter or non-reimbursed drugs, such as analgesics, antacids, laxatives or supplements. We cannot estimate the medication used by those mothers whose EHR have not been linked to their infants either, also resulting in lower prevalence estimates. Despite these limitations, studies conducted with EHR have several strengths which can help to identify commonly used medications during lactation and prioritize research on their safety, such as the mother-infant linked information, long follow-up and thorough registries including valuable information. Some of the frequently used medications observed in our study have insufficient or inadequate data available regarding the effects on lactating infants, such as SSRI, certain proton-pump inhibitors, or metamizole. 10 Those drugs could be prioritized in future safety studies in lactating mothers. More studies covering the limitations mentioned are still needed, in order to analyze the safety of using drugs during lactation both in the mothers and the infants’ health. Also, more tools to help decision making for prescribers are necessary for the purpose of selecting safe and lactation-compatible drugs. Conclusions The number of lactating and drug-exposed mothers decreased over time. Iron and supplements were the most used drugs, mainly during the first two months, probably due to continuation since pregnancy or post-partum anemia. Analgesics and penicillins were also frequent, which might be used for common acute conditions. Despite the limitations, our study conducted with EHR add evidence which may help to identify commonly used drugs during lactation and prioritize further studies on their safety. Abbreviations ASSIR: Sexual and reproductive healthcare. ATC: Anatomical Therapeutic Chemical CLASSIFICATION. ECAP: electronic health records in Catalonia. EHR: Electronic Health Records. FDA: United States Food and Drug Administration. ICD-10-CM: International Classification of Diseases, 10 th revision, Clinical Modification. MEDEA: socioeconomic index, Mortalidad en áreas pequeñas Españolas y Desigualdades socio-Económicas y Ambientales . NSAID: non-steroidal anti-inflammatory drug. PREFASEG: Safe Pharmacological Prescription. SIDIAP: Information System for Research in Primary Care. SSRI: selective-serotonin reuptake inhibitors. Declarations Ethics approval and consent to participate The study protocol was approved by the Research Ethics Committee of IDIAPJGol (January 2023, project number 22/102-P). This is a database research study which has been conducted according to the guidelines of the Declaration of Helsinki (Helsinki, Finland 2024) and does not require consent from the people included to participate. The need for consent was waived by the Research Ethics Committee of IDIAPJGol as it is deemed unnecessary according to European legislation (Regulation [EU] 2016/679) and Spanish legislation (Ley Orgánica 3/2018, dated 6 December 2018, de Protección de Datos Personales y garantía de los derechos digitales). Consent for publication Not applicable, as the study did not require consent from people included to participate either. Availability of data and materials The datasets generated and/or analysed during the current study are not publicly available due to patient privacy and data protection concerns, but they are available from the corresponding author on reasonable request. All data generated or analysed during this study are included in this published article and its supplementary information files. Competing interests The authors have no relevant financial or non-financial interests to disclose. Funding This study received funding from the Health Department of the Generalitat de Catalunya, in the 2021 call for the “Strategic Plan for Research and Innovation in Health (PERIS) 2022-2024, Research Projects in Primary Care”, expedient number SLT021/21/000068. Authors' contributions Conceptualization: MGS, AGL, RM, CV. Data acquisition: MGS, RM. Data curation: GAR, ACH. Formal analysis: GAR. Funding acquisition: MGS, AGL, MLV, RM, CV. Investigation: all authors. Methodology: all authors. Project administration: MGS, CV. Software: GAR, ACH. Resources: all authors. Supervision: MGS, ACH, RM. Validation: all authors. Visualization: GAR, ACH. Writing – original draft: MGS. Writing – review and editing: all authors. Acknowledgements The authors want to thank SIDIAP team for their work in maintaining the database and for their help in the data acquisition. References CHMP. EMEA/CHMP/313666/2005 - Guideline on the Exposure to Medicinal Products During Pregnancy: Need for Post-Authorisation Data. European Medicines Agency. 2005;(November):21. McGregor AJ, Hasnain M, Sandberg K, Morrison MF, Berlin M, Trott J. How to study the impact of sex and gender in medical research: A review of resources. Biol Sex Differ [Internet]. 2016;7(Suppl 1). Available from: http://dx.doi.org/10.1186/s13293-016-0099-1 Mauvais-Jarvis F, Bairey Merz N, Barnes PJ, Brinton RD, Carrero JJ, DeMeo DL, et al. Sex and gender: modifiers of health, disease, and medicine. The Lancet [Internet]. 2020;396(10250):565–82. Available from: http://dx.doi.org/10.1016/S0140-6736(20)31561-0 Briggs G, Freeman R, Yaffe S. Drugs in pregnancy and lactation: a reference and neonatal risk. 10th ed. Wolters Kluwer Health, editor. Philadelphia, USA; 2015. Pernia S, Demaagd G. The new pregnancy and lactation labeling rule. P and T. 2016;41(11):713–5. FDA. Content and format of labeling for human prescription drug and biological products; requirements for pregnancy and lactation labeling. Final rule. Fed Regist. 2014;79(233):72063–103. European Medicines Agency. Guideline on good pharmacovigilance practices (GVP) - Product- or Population-Specific Considerations III: Pregnant and breastfeeding women [Internet]. 2019 Dec [cited 2025 Feb 3]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-good-pharmacovigilance-practices-product-population-specific-considerations-iii_en.pdf McClatchey AK, Shield A, Cheong LH, Ferguson SL, Cooper GM, Kyle GJ. Why does the need for medication become a barrier to breastfeeding? A narrative review. Women and Birth. 2018 Oct 1;31(5):362–6. Paricio-Talayero JM, Mena-Tudela D, Cervera-Gasch Á, González-Chordá VM, Paricio-Burtin Y, Sánchez-Palomares M, et al. Is it compatible with breastfeeding? www.e-lactancia.org: Analysis of visits, user profile and most visited products. Int J Med Inform. 2020 Sep 1;141:104199. e-lactancia.org. APILAM: Asociación para la promoción e investigación científica y cultural de la lactancia materna [Internet]. actualizado 03 feb 2025. 2002 [cited 2025 Feb 4]. Available from: https://e-lactancia.org ECAP blog. ECAP; Estació clínica d’atenció primària [Internet]. Available from: https://ecapics.wordpress.com/about/ Catalán A, Borrell F, Pons À, Amado E, Baena JM, Morales V. Seguridad del paciente en atención primaria: proyecto PREFASEG (PREscripción FArmacológica SEGura). Med Clin (Barc). 2014 Jul 1;143(SUPPL. 1):32–5. Mohamed HH, Ehresmann K, Seburg EM, Vazquez‐Benitez G, Demerath EW, Fields DA, et al. Characterisation and validation of lactation information from structured electronic health records for use in pharmacoepidemiological studies. Paediatr Perinat Epidemiol [Internet]. 2024 Aug 17 [cited 2024 Sep 2];38(6):505–14. Available from: https://onlinelibrary.wiley.com/doi/10.1111/ppe.13051 Thurin NH, Pajouheshnia R, Roberto G, Dodd C, Hyeraci G, Bartolini C, et al. From Inception to ConcePTION: Genesis of a Network to Support Better Monitoring and Communication of Medication Safety During Pregnancy and Breastfeeding. Clin Pharmacol Ther [Internet]. 2022 Jan 26;111(1):321–31. Available from: https://onlinelibrary.wiley.com/doi/10.1002/cpt.2476 Palmsten K, Vazquez-Benitez G, JaKa MM, Bandoli G, Ahrens KA, Kharbanda EO. The most common medications dispensed to lactating persons: An electronic health record-based approach. Pharmacoepidemiol Drug Saf. 2023 Oct 1;32(10):1113–20. Leggett C, Costi L, Morrison JL, Clifton VL, Grzeskowiak LE. Antidepressant Use in Late Gestation and Breastfeeding Rates at Discharge from Hospital. Journal of Human Lactation. 2017 Nov 1;33(4):701–9. Malm H, Martikainen J, Klaukka T, Neuvonen PJ. Prescription drugs during pregnancy and lactation - A Finnish register-based study. Eur J Clin Pharmacol. 2003 Jun 1;59(2):127–33. SIDIAP. SIDIAP. Information system for research in Primary Care [Internet]. SIDIAP. 2023. Available from: http://www.sidiap.org/index.php/en Recalde M, Rodríguez C, Burn E, Far M, García D, Carrere-Molina J, et al. Data Resource Profile: The Information System for Research in Primary Care (SIDIAP). Int J Epidemiol [Internet]. 2022 Apr 13;1–13. Available from: https://academic.oup.com/ije/advance-article/doi/10.1093/ije/dyac068/6567646 Departament de Salut G de C. CIM-10-MC/SCP [Internet]. Available from: https://catsalut.gencat.cat/ca/proveidors-professionals/registres-catalegs/catalegs/diagnostics-procediments/cim-10-mc-scp/ Departament de Salut. Generalitat de Catalunya. Protocol d’activitats preventives i de promoció de la salut a l’edat pediàtrica: créixer amb salut [Internet]. 2025 [cited 2025 Feb 11]. Available from: https://hdl.handle.net/11351/1197.2 WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD Index 2025 [Internet]. 2025. Available from: https://www.whocc.no/atc_ddd_index/ Segundo E, Far M, Rodríguez-Casado CI, Elorza JM, Carrere-Molina J, Mallol-Parera R, et al. A mother-child data linkage approach using data from the information system for the development of research in primary care (SIDIAP) in Catalonia. J Biomed Inform. 2024 Nov 1;159. Domínguez-Berjón M, Borrell C, Cano-Serral G, Esnaola S, Nolasco A, Pasarin M, et al. Construcción de un índice de privación a partir de datos censales en grandes ciudades españolas (Proyecto MEDEA). Gac Sanit. 2008;22(3):179–87. World Health Organization W. Breastfeeding recommendations, WHO [Internet]. WHO. 2025 [cited 2025 Feb 11]. Available from: https://www.who.int/health-topics/breastfeeding#tab=tab_1 Seguridad Social. Ministerio de Inclusión SS y M. Rest periods in relation to the Workers’ Statute (ET), birth and child care [Internet]. Art. 48.4, 5 and 6 of the Workers’ Statute (ET). 2025 [cited 2025 Feb 11]. Available from: https://www.seg-social.es/wps/portal/wss/internet/Trabajadores/PrestacionesPensionesTrabajadores/6b96a085-4dc0-47af-b2cb-97e00716791e/0b5879ed-1156-4676-b38c-7229dcba9c49?changeLanguage=en Martín-Ramos S, Domínguez-Aurrecoechea B, García Vera C, Lorente García Mauriño AM, Sánchez Almeida E, Solís-Sánchez G. Lactancia materna en España y factores relacionados con su instauración y mantenimiento: estudio LAyDI (PAPenRed). Aten Primaria. 2024 Jan 1;56(1):102772. Vila-Candel R, Soriano-Vidal FJ, Franco-Antonio C, Garcia-Algar O, Andreu-Fernandez V, Mena-Tudela D. Factors Influencing Duration of Breastfeeding: Insights from a Prospective Study of Maternal Health Literacy and Obstetric Practices. Nutrients [Internet]. 2024 Mar 1 [cited 2025 Feb 11];16(5):690. Available from: https://www.mdpi.com/2072-6643/16/5/690/htm Ortega-Ramírez AD, Maneschy IR, Miguel-Berges ML, Pastor-Villaescusa B, Leis R, Babio N, et al. Early feeding practices and eating behaviour in preschool children: The CORALS cohort. Matern Child Nutr. 2024 Oct 1; Mena-Tudela D, Soriano-Vidal FJ, Vila-Candel R, Quesada JA, Martínez-Porcar C, Martin-Moreno JM. Is Early Initiation of Maternal Lactation a Significant Determinant for Continuing Exclusive Breastfeeding up to 6 Months? International Journal of Environmental Research and Public Health 2023, Vol 20, Page 3184 [Internet]. 2023 Feb 11 [cited 2024 Dec 10];20(4):3184. Available from: https://www.mdpi.com/1660-4601/20/4/3184/htm Martín-Ramos S, Domínguez-Aurrecoechea B, García Vera C, Lorente García Mauriño AM, Sánchez Almeida E, Solís-Sánchez G. Lactancia materna en España y factores relacionados con su instauración y mantenimiento: estudio LAyDI (PAPenRed). Aten Primaria [Internet]. 2024 Jan 1 [cited 2025 May 28];56(1):102772. Available from: https://www.sciencedirect.com/science/article/pii/S0212656723002056?via%3Dihub Martín-Ramos S, Domínguez-Aurrecoechea B, Sánchez Echenique M, Garcia Pérez R, Bonet Garrosa A, Solís-Sánchez G. Breastfeeding duration and nutritional status of infants and toddlers in Spain. LAyDI study (PAPenRed). Anales de Pediatría (English Edition). 2024 Sep 1;101(3):172–82. Infante-Torres N, Molina-Alarcón M, Rubio-Álvarez A, Rodríguez-Almagro J, Hernández-Martínez A. Relationship between duration of second stage of labour and postpartum anaemia. Women and Birth. 2018 Oct 1;31(5):e318–24. Rubio-Álvarez A, Molina-Alarcón M, Hernández-Martínez A. Incidence of postpartum anaemia and risk factors associated with vaginal birth. Women and Birth. 2018 Jun 1;31(3):158–65. Medina Garrido C, León J, Romaní Vidal A. Maternal anaemia after delivery: prevalence and risk factors. J Obstet Gynaecol (Lahore) [Internet]. 2018 Jan 2 [cited 2025 Feb 11];38(1):55–9. Available from: https://www.tandfonline.com/doi/abs/10.1080/01443615.2017.1328669 Urquizu I Brichs X, Rodriguez Carballeira M, García Fernández A, Perez E, Nol P. Anaemia in pregnancy and in the immediate postpartum period. Prevalence and risk factors in pregnancy and childbirth. Vol. 146, Med Clin (Barc). 2016. Mary ST, Antonio DCC, Stephane D, Michael A, Francesca G, Claude B, et al. Subclinical Mastitis in a European Multicenter Cohort: Prevalence, Impact on Human Milk (HM) Composition, and Association with Infant HM Intake and Growth. Nutrients 2020, Vol 12, Page 105 [Internet]. 2019 Dec 30 [cited 2025 Feb 11];12(1):105. Available from: https://www.mdpi.com/2072-6643/12/1/105/htm Amir LH. ABM Clinical Protocol #4: Mastitis, Revised March 2014. Breastfeeding Medicine [Internet]. 2014 Jun [cited 2025 Feb 4];9(5):239–43. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4048576/pdf/bfm.2014.9984.pdf Espínola-Docio B, Costa-Romero M, Díaz-Gómez M, Paricio-Talayero JM. Mastitis. Puesta al día. Arch Argent Pediatr. 2016 Dec 1;114(6). Paricio Talayero JM. Diagnóstico y manejo de la mastitis en la madre lactante. Actualización. In: IX Congreso Español de Lactancia Materna [Internet]. 2017 [cited 2025 Feb 4]. Available from: https://www.e-lactancia.org/media/papers/Mastitis_Texto-CongrLM_Zar-Paricio.pdf Lutz BH, Bassani DG, Miranda VIA, Silveira MPT, Mengue SS, Dal Pizzol T da S, et al. Use of medications by breastfeeding women in the 2015 pelotas (Brazil) birth cohort study. Int J Environ Res Public Health. 2020 Jan 2;17(2). de Waard M, Blomjous BS, Hol MLF, Sie SD, Corpeleijn WE, van Goudoever J (Hans) B, et al. Medication Use During Pregnancy and Lactation in a Dutch Population. Journal of Human Lactation [Internet]. 2019 Feb 3;35(1):154–64. Available from: https://journals.sagepub.com/doi/10.1177/0890334418775630 Campbell SC, Kast TT, Kamyar M, Robertson J, Sherwin CM. Calls to a teratogen information service regarding potential exposures in pregnancy and breastfeeding. BMC Pharmacol Toxicol [Internet]. 2016 Jul 23 [cited 2025 Feb 12];17(1):1–6. Available from: https://bmcpharmacoltoxicol.biomedcentral.com/articles/10.1186/s40360-016-0076-7 Gorman JR, Kao K, Chambers CD. Breastfeeding among women exposed to antidepressants during pregnancy. Journal of Human Lactation [Internet]. 2012 May [cited 2025 Feb 12];28(2):181–8. Available from: http://jhl.sagepub.com Jordan S, Davies GI, Thayer DS, Tucker D, Humphreys I. Antidepressant prescriptions, discontinuation, depression and perinatal outcomes, including breastfeeding: A population cohort analysis. PLoS One. 2019 Nov 1;14(11). Tables Table 1. Baseline sociodemographic and clinical characteristics of mothers linked to infants receiving breast milk after birth SD: standard deviation. IQR: interquartile range MEDEA: socioeconomic index of one rural category and five urban categories/quintiles. Table 2. Drug exposure in mothers during the 12 after birth. Mother exposed to drugs during all the study period N= 96,094 Drugs Total exposure over the 12 months, n (%) More frequent drug, n (%*) Oral iron 44,102 (25.0) Ferrous sulfate, 31,406 (71.2) Analgesics 31,102 (17.7) Paracetamol, 28,068 (90.2) Folic acid 27,396 (15.5) Folic acid, 27,396 (100.0) Beta-lactam antibacterials 25,536 (14.5) Amoxicillin, 22,984 (90.0) NSAID 24,114 (13.7) Ibuprofen, 18,224 (75.6) Vitamin B12 22,604 (12.8) Cyanocobalamin, 22,604 (100.0) Gynecological anti-infectives/antiseptics 6,473 (3.7) Clotrimazole (topical), 3,784 (58.5) Other antibacterials 5,975 (3.4) Fosfomycin, 5,340 (89.4) Systemic antihistamines 5,323 (3.0) Cetirizine, 1,855 (34.8) Heparins 5,107 (2.9) Enoxaparin, 3,574 (70.0) Thyroid hormones 3,723 (2.1) Levothyroxine, 3,722 (100.0) Beta-2-adrenoceptor agonists, inhaled 3,172 (1.8) Salbutamol, 2,176 (68.6) Proton pump inhibitors 2,902 (1.7) Omeprazole, 2,716 (93.4) Macrolides 2,295 (1.3) Azithromycin, 1,062 (46.3) Glucocorticoids inhaled 2,136 (1.2) Budesonide, 1,548 (72.5) Anxiolytics, hypnotics and sedatives 1,880 (1.1) Diazepam, 683 (36.3) H2 – receptor antagonists 1,804 (1.0) Ranitidine, 1,766 (97.9) Other systemic hormonal preparations, excluding sex hormones and insulins 1,656 (0.94) Prednisone, 1,117 (67.5) SSRI antidepressants 1,645 (0.93) Sertraline, 457 (27.8) Laxatives 1,632 (0.93) Ispaghula, 1,041 (63.8) Beta-blockers 1,586 (0.9) Labetalol, 1,409 (88.8) Other beta-lactam antibacterials 1,532 (0.87) Cefuroxime, 971 (63.4) Quinolones 1,455 (0.83) Ciprofloxacin, 1,088 (74.8) Vitamins 1,162 (0.66) Cholecalciferol, 1,041 (89.6) *% calculated on the overall exposure of the group. NSAID: non-steroidal anti-inflammatory drugs. SSRI: selective-serotonin reuptake inhibitors Additional Declarations No competing interests reported. Supplementary Files Supplementarytables.docx Cite Share Download PDF Status: Published Journal Publication published 24 Dec, 2025 Read the published version in International Breastfeeding Journal → Version 1 posted Editorial decision: Revision requested 17 Oct, 2025 Reviews received at journal 17 Oct, 2025 Reviewers agreed at journal 29 Sep, 2025 Reviews received at journal 11 Sep, 2025 Reviewers agreed at journal 21 Aug, 2025 Reviewers invited by journal 15 Aug, 2025 Editor assigned by journal 12 Jul, 2025 Submission checks completed at journal 12 Jul, 2025 First submitted to journal 10 Jul, 2025 You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-7091470","acceptedTermsAndConditions":true,"allowDirectSubmit":false,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":503848412,"identity":"1a1f5377-55a9-4e6f-88ea-957c37607477","order_by":0,"name":"Maria Giner-Soriano","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAA80lEQVRIie2QvQrCMBCArxTqcrZrguIbCO1SHURfRRF8BdeKEBfR1d13cHKIdOgidi24KEJnXUSkg6eibrGjYL7hcsN9uR8AjeYnMQIKDYSQHgZQBhPgmEPpvRUkxZjlaEX18pnh/RelUp3Oxe60jMt2ZKa7+pUmLBRXgWoyP9mPvFm6RR5aNZdPaELT7gxUbfxkJUoot+iG4DM+DknB2gG/KZnckFI4vxRvqFTigSiBlKSgz9glj5IYgo9ll3bBvsuDHlqkqHeJo5RdZLNlx9HiwLJGxXHWnvJiwNrv1DK5oKiqfuDIj2Ics6/1Go1G84fcAHUXTJBf0nj0AAAAAElFTkSuQmCC","orcid":"","institution":"Fundació Institut Universitari per a la Recerca a l’Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol)","correspondingAuthor":true,"prefix":"","firstName":"Maria","middleName":"","lastName":"Giner-Soriano","suffix":""},{"id":503848413,"identity":"37c9619c-38ba-4cc9-a949-06c6fc2adb2f","order_by":1,"name":"Guim Arbona Ricart","email":"","orcid":"","institution":"Universitat Autònoma de Barcelona","correspondingAuthor":false,"prefix":"","firstName":"Guim","middleName":"Arbona","lastName":"Ricart","suffix":""},{"id":503848414,"identity":"b6b6a487-592b-4b83-b97a-96b61312aba8","order_by":2,"name":"Àurea Cartanyà-Hueso","email":"","orcid":"","institution":"Fundació Institut Universitari per a la Recerca a l’Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol)","correspondingAuthor":false,"prefix":"","firstName":"Àurea","middleName":"","lastName":"Cartanyà-Hueso","suffix":""},{"id":503848415,"identity":"e85c3dc4-ad54-42e7-8f98-4daf004e6cb6","order_by":3,"name":"Ainhoa Gomez-Lumbreras","email":"","orcid":"","institution":"University of Utah","correspondingAuthor":false,"prefix":"","firstName":"Ainhoa","middleName":"","lastName":"Gomez-Lumbreras","suffix":""},{"id":503848416,"identity":"686d8ea4-c1bb-4c9b-8ad0-358a8eb4ca6e","order_by":4,"name":"Marta Lestón Vázquez","email":"","orcid":"","institution":"Àrea del Medicament i Servei de Farmàcia, Gerència d'Atenció Primària Barcelona Ciutat, Institut Català de la Salut","correspondingAuthor":false,"prefix":"","firstName":"Marta","middleName":"Lestón","lastName":"Vázquez","suffix":""},{"id":503848417,"identity":"08e49792-6ba9-46cc-bbdd-e3db7b633cd3","order_by":5,"name":"Rosa Morros","email":"","orcid":"","institution":"Fundació Institut Universitari per a la Recerca a l’Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol)","correspondingAuthor":false,"prefix":"","firstName":"Rosa","middleName":"","lastName":"Morros","suffix":""},{"id":503848418,"identity":"a2aa6ca6-a0a3-4daf-89ed-4eeee75f94b9","order_by":6,"name":"Cristina Vedia","email":"","orcid":"","institution":"Unitat de farmàcia, Gerència d’Atenció Primària i Comunitària Barcelonès Nord i Maresme","correspondingAuthor":false,"prefix":"","firstName":"Cristina","middleName":"","lastName":"Vedia","suffix":""}],"badges":[],"createdAt":"2025-07-10 09:38:53","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-7091470/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-7091470/v1","draftVersion":[],"editorialEvents":[{"content":"https://doi.org/10.1186/s13006-025-00797-3","type":"published","date":"2025-12-24T15:58:30+00:00"}],"editorialNote":"","failedWorkflow":false,"files":[{"id":89974508,"identity":"2cf80dd5-e8a3-4949-ac33-7984fad3e367","added_by":"auto","created_at":"2025-08-27 05:54:37","extension":"png","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":103212,"visible":true,"origin":"","legend":"\u003cp\u003eFlowchart of study inclusion\u003c/p\u003e","description":"","filename":"Figure1.png","url":"https://assets-eu.researchsquare.com/files/rs-7091470/v1/617f1debeae81e8963c62990.png"},{"id":89974503,"identity":"a64a8ead-6e1e-4e5e-8c63-30e95681165a","added_by":"auto","created_at":"2025-08-27 05:54:36","extension":"jpg","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":379326,"visible":true,"origin":"","legend":"\u003cp\u003eDistribution of infants of the mother-infant cohort by calendar year of birth and with breastfeeding registers at each time-cut\u003c/p\u003e","description":"","filename":"Figure2.jpg","url":"https://assets-eu.researchsquare.com/files/rs-7091470/v1/e8bc7fe5154b8e771436b919.jpg"},{"id":89976331,"identity":"3f28347d-c32a-4bde-8840-dea793bda0af","added_by":"auto","created_at":"2025-08-27 06:02:36","extension":"jpg","order_by":3,"title":"Figure 3","display":"","copyAsset":false,"role":"figure","size":316122,"visible":true,"origin":"","legend":"\u003cp\u003eFrequency of mothers exposed to drugs at the four time-cuts analyzed (2, 4, 6 and 12 months)\u003c/p\u003e\n\u003cp\u003eNSAID: non-steroidal anti-inflammatory drugs\u003c/p\u003e","description":"","filename":"Figure3.jpg","url":"https://assets-eu.researchsquare.com/files/rs-7091470/v1/c82b220d9f764977c8acefcf.jpg"},{"id":99172421,"identity":"928e0de1-8eb8-45ae-9623-32f3f6ae46c6","added_by":"auto","created_at":"2025-12-29 16:09:16","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":1573128,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-7091470/v1/e9d64a6e-5248-4c3c-875b-a4d5f058a129.pdf"},{"id":89977612,"identity":"d41958b4-e602-4533-9847-0dacfca81294","added_by":"auto","created_at":"2025-08-27 06:10:36","extension":"docx","order_by":0,"title":"","display":"","copyAsset":false,"role":"supplement","size":32319,"visible":true,"origin":"","legend":"","description":"","filename":"Supplementarytables.docx","url":"https://assets-eu.researchsquare.com/files/rs-7091470/v1/79f67084f11e9dcc263aed54.docx"}],"financialInterests":"No competing interests reported.","formattedTitle":"Drug exposure during breastfeeding: a descriptive population- based cohort study with SIDIAP database","fulltext":[{"header":"Background","content":"\u003cp\u003ePregnancy and breastfeeding are physiological process in females’ fertility life where there is a lack of comprehensive data on drug safety due to the exclusion of pregnant and lactating individuals from clinical trials and other studies for ethical reasons and due to the generalised under-investigation in women’s health.\u003csup\u003e\u003cspan additionalcitationids=\"CR2 CR3\" citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e–\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e\u003cp\u003eIn 2015, the United States Food and Drug Administration (FDA) implemented the Pregnancy and Lactation Labelling Rule to assist in the prescription decision making process during pregnancy and lactation requiring a narrative description of the risks and clinical considerations of drugs differentiated into three sections: gestation (including childbirth), lactation and, reproductive potential in men and women.\u003csup\u003e\u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e,\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e\u003c/sup\u003e The European Medicines Agency establishes in its Good Practice Guide on Pharmacovigilance for specific populations – pregnant and breastfeeding women – that it is necessary to carry out post authorization observational safety studies on those drugs that cannot be discontinued during pregnancy, drugs to treat gestational/lactational diseases or drugs that in preclinical studies have shown some type of risk for the offspring.\u003csup\u003e\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e\u003cp\u003eDespite the warnings on the use of some drugs in pregnancy or breastfeeding, it is not always advisable to discontinue some chronic drug treatments due to an increased risk of disease complications in the mother or offspring.\u003csup\u003e\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e,\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e\u003c/sup\u003e In Spain, the tool e-lactancia.org is widely used by healthcare professionals to search for information on drug exposure during breastfeeding and as providers seen it useful during the prescription process.\u003csup\u003e\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e\u003c/sup\u003e It classifies the drugs in one of four categories, according to their compatibility to be administered while breastfeeding.\u003csup\u003e\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e\u003c/sup\u003e The electronic health records in Catalonia (ECAP)\u003csup\u003e\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e\u003c/sup\u003e include the PREFASEG (Safe Pharmacological Prescription) tool in the prescription software, which alerts on drug-drug interactions, allergies, duplicated treatments and contraindications, and includes alerts related to pregnancy and lactation.\u003csup\u003e\u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e\u003c/sup\u003e However, lactating individuals and their healthcare professionals often lack data to support their decisions on medication use. This gap in knowledge makes it challenging to fully understand the implication of drug use while breastfeeding and potential risks to newborns, as some drugs may pass into breast milk.\u003csup\u003e\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e\u003cp\u003eBreastfeeding information stored in the electronic health records (EHR) can be used for pharmacoepidemiology research.\u003csup\u003e\u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e,\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e\u003c/sup\u003e Some population-based studies have been conducted to fill in this gap, as healthcare databases offer numerous advantages when studying the safety of drug use during lactation.\u003csup\u003e\u003cspan additionalcitationids=\"CR16\" citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e–\u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e\u003c/sup\u003e As mother-infant linked information is available in our database, it is possible to study drug exposure in mothers during breastfeeding.\u003c/p\u003e\u003cp\u003eFor this reason, we aimed to describe drug exposure during breastfeeding in mothers of a cohort of mother-infant linked pairs in Catalonia, Spain.\u003c/p\u003e"},{"header":"Methods","content":"\u003cp\u003eDesign and study populations\u003c/p\u003e\u003cp\u003eDescriptive observational study using a population-based cohort of mother-infant linked pairs. The populations included mothers and infants with linked EHR.\u003c/p\u003e\u003cp\u003eStudy period\u003c/p\u003e\u003cp\u003eWe analyzed the information available for those mother-infant linked pairs for infants born from January 2010 to December 2022.\u003c/p\u003e\u003cp\u003eData source\u003c/p\u003e\u003cp\u003eThe study data source was SIDIAP, which captures clinical information of 5.8\u0026nbsp;million people from Catalonia, Spain.\u003csup\u003e\u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e,\u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e\u003c/sup\u003e SIDIAP database is pseudonymized and contains information from different data sources: 1) EHR in primary health care of the Catalan Health Institute (approximately attending 75% of the Catalan population); including sociodemographic characteristics, comorbidities registered as International Classification of Diseases, 10th revision, Clinical Modification (ICD­10-CM) codes (Supplementary Table \u003cspan refid=\"MOESM1\" class=\"InternalRef\"\u003eS1\u003c/span\u003e),\u003csup\u003e\u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e\u003c/sup\u003e specialist referrals, clinical parameters, toxic habits, sickness leave, date of death, laboratory test, pediatric visits,\u003csup\u003e\u003cspan citationid=\"CR21\" class=\"CitationRef\"\u003e21\u003c/span\u003e\u003c/sup\u003e and drug prescriptions issued in Primary Health Care, registered as Anatomical Therapeutic Chemical (ATC) classification system codes (Supplementary Table S2).\u003csup\u003e\u003cspan citationid=\"CR22\" class=\"CitationRef\"\u003e22\u003c/span\u003e\u003c/sup\u003e 2) Sexual and reproductive healthcare (ASSIR) records, which is the EHR module used by gynecologists and midwives to register variables related with the sexual and reproductive health of women and follow-up of pregnancies. 3) Pharmacy invoice data corresponding to the Primary Care drug prescriptions, classified according to the ATC classification. \u003csup\u003e\u003cspan citationid=\"CR24\" class=\"CitationRef\"\u003e24\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e\u003cp\u003eSIDIAP has established an algorithm that links mothers with their offspring.\u003csup\u003e\u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e\u003c/sup\u003e This algorithm was applied to identify the mother-infant pairs of interest for this study. We included all children born in 2010–2022 linked to their mothers with lactation registers in their EHR.\u003c/p\u003e\u003cp\u003eVariables\u003c/p\u003e\u003cp\u003eVariables were retrieved from the mother-infant pairs as follows:\u003c/p\u003e\u003cp\u003e\u003cspan type=\"Underline\" class=\"Underline\" name=\"Emphasis\"\u003eInfants’ variables\u003c/span\u003e; sociodemographic variables (age and sex) and registers of lactation in the EHR during the first 12 months after birth.\u003c/p\u003e\u003cp\u003e\u003cspan type=\"Underline\" class=\"Underline\" name=\"Emphasis\"\u003eMaternal variables\u003c/span\u003e; sociodemographic variables (age and MEDEA socioeconomic index\u003csup\u003e\u003cspan citationid=\"CR24\" class=\"CitationRef\"\u003e24\u003c/span\u003e\u003c/sup\u003e), comorbidities up to delivery date, pregnancy follow-up variables (e.g. gestational week, delivery procedures), drug exposure during the first year of breastfeeding. We analyzed the drug exposure from delivery up to four time-cuts after birth while lactating: in the first 2 months, from months 2 to 4, from months 4 and 6 and from 6 up to 12 months.\u003c/p\u003e\u003ch2\u003eStatistical analysis\u003c/h2\u003e\u003cp\u003eWe described maternal and infant characteristics by absolute frequency and percentage categorical variables and by mean and standard deviation, and median and interquartile range continuous variables. In addition, we calculated the prevalences of drug use during breastfeeding, during first two months, between the third and fourth months, between fifth and sixth months, between seventh and twelfth months and during the first year. Drugs used by at least 0.5% of mothers at any time points were described.\u003c/p\u003e"},{"header":"Results","content":"\u003cp\u003eWe identified 176,324 mother-infant pairs with breastfeeding registers during the first year after birth in our study period (Figure 1).\u003c/p\u003e\n\u003cp\u003eInfants receiving breast milk decreased progressively through the first year of life, from 176,324 to 148,413 (84.2%) during months 2 to 4, 98,635 (55.9%) during months 4 to 6, and 64,225 (36.4%) from months 6 to 12. The mean duration of the breastfeeding was 6.2 months (SD 3.8) and the median, 6.0 (IQR 3.0-9.0). The distribution of infants and their breastfeeding records from 2010 to 2022 is shown in Figure 2. The proportion of breastfed infants for up to 2 months increased approximately from 2017 to 2022, while the proportion of infants receiving breastfeeding up to 4 months decreased. The proportions for the other two time-cuts are stable. The proportions in 2022 do not follow the same pattern due to the censoring of the end of study period.\u003c/p\u003e\n\u003cp\u003eBaseline mothers’ characteristics are described in Table 1. They had a mean age of 32.3 years (SD 5.5), their MEDEA socioeconomic index was rural for 25,765 of them (17.6%), and 65,823 (45.1%) lived in the least deprived urban areas. Smoking habit was registered during pregnancy or the previous 12 months only for 33,079 (18.8%) of the mothers, being 5,814 (17.6%) current smokers. Body mass index was registered during pregnancy or the previous 12 months only for 39,689 (22.5%) of the mothers and 19,003 of them (47.9%) overweight or obese. \u0026nbsp;More than half of the mothers had at least one comorbidity (N= 96,635, 54.8%), psychiatric diagnoses were the most frequent ones (24.9%), followed by obesity (9.4%). More than half of the mothers were exposed to drugs 96,094 (54.5%) during the first year after delivery.\u003c/p\u003e\n\u003cp\u003eMothers exposed to drugs varied from 76,064 (43.1% of the lactating mothers) from delivery up to month 2, to 32,475 (21.9%), 17,396 (17.6%) and 20,433 (31.8%) at up to months 4, 6 and 12, respectively (Figure 3).\u003c/p\u003e\n\u003cp\u003eTable 2 includes the most dispensed pharmacological groups over the 12 months analyzed in at least 0.5% of the mothers. We also describe the most frequent drug of each group. Iron (25%), folic acid (15.5%) and analgesics (17.7%) were the most frequently used drugs by breastfeeding mothers. Paracetamol was the most frequent analgesic (90.2% of all analgesics), amoxicillin and fosfomycin were the most frequent antibiotics (90% and 89.4% of their corresponding groups), or ibuprofen the most frequent non-steroidal anti-inflammatory drug (NSAID, 75.6%). \u0026nbsp;\u003c/p\u003e\n\u003cp\u003eFigure 3 includes the 10 most frequent pharmacological groups dispensed at the four time-cuts analyzed. The most common ones at month 2 were iron (23.2%), folic acid (14.7%), vitamin B12 (12%) and analgesics (10.6%). All pharmacological groups decreased their exposure in subsequent time-cuts. \u0026nbsp;In the Supplementary Table S3 we have included all pharmacological groups dispensed in at least 0.5% of the mothers in any of the four time-cuts studied.\u0026nbsp;\u003c/p\u003e"},{"header":"Discussion","content":"\u003cp\u003eWe studied 176,324 mother-infant pairs with lactation registries during the 12 months after birth to analyze the drug exposure of the mothers during the lactation period. The number of breastfed infants decreased over time after birth and the lactating mothers exposed to drugs also decreased up to 6 months, to further increase from months 7 to 12.\u003c/p\u003e\u003cp\u003eAs expected, the number of infants receiving breast milk progressively diminished during the first year of life, with a mean duration of 6.2 months, as they usually start food other than milk at month 6,\u003csup\u003e\u003cspan citationid=\"CR21\" class=\"CitationRef\"\u003e21\u003c/span\u003e,\u003cspan citationid=\"CR25\" class=\"CitationRef\"\u003e25\u003c/span\u003e\u003c/sup\u003e and the mandatory duration of maternity leave in Spain is 16 weeks,\u003csup\u003e\u003cspan citationid=\"CR26\" class=\"CitationRef\"\u003e26\u003c/span\u003e\u003c/sup\u003e hindering the maintenance of exclusive breastfeeding even before the World Health Organization recommendations.\u003csup\u003e\u003cspan citationid=\"CR25\" class=\"CitationRef\"\u003e25\u003c/span\u003e\u003c/sup\u003e In fact, some studies in Spain have reported breastfeeding duration in different cohorts and they also found decrease in the number of infants receiving breast milk, stopping before guidelines recommendations.\u003csup\u003e\u003cspan additionalcitationids=\"CR28 CR29\" citationid=\"CR27\" class=\"CitationRef\"\u003e27\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR30\" class=\"CitationRef\"\u003e30\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e\u003cp\u003eThe number of lactating mothers exposed to drugs decreased from month 2 to months 4 and 6, but slightly increased at month 12. The decrease may be caused by the mother\u0026rsquo;s awareness of the potential harms of drug exposure to lactating infants,\u003csup\u003e\u003cspan citationid=\"CR31\" class=\"CitationRef\"\u003e31\u003c/span\u003e\u003c/sup\u003e whereas the increase from months 6 to 12 could be caused by the reduction of numbers of breastfeeding sessions over time as the infant grows,\u003csup\u003e\u003cspan citationid=\"CR28\" class=\"CitationRef\"\u003e28\u003c/span\u003e,\u003cspan citationid=\"CR30\" class=\"CitationRef\"\u003e30\u003c/span\u003e,\u003cspan citationid=\"CR32\" class=\"CitationRef\"\u003e32\u003c/span\u003e\u003c/sup\u003e thus the mothers get exposed to drugs more frequently.\u003c/p\u003e\u003cp\u003eRegarding drug exposure, iron and vitamin supplements were the most used drugs by breastfeeding women, mainly during the first 2 months after birth, probably due to continuation since pregnancy or due to postpartum anemia in the case of iron, which is a relatively frequent condition.\u003csup\u003e\u003cspan additionalcitationids=\"CR34 CR35\" citationid=\"CR33\" class=\"CitationRef\"\u003e33\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR36\" class=\"CitationRef\"\u003e36\u003c/span\u003e\u003c/sup\u003e Penicillins were also frequently dispensed during breastfeeding, which might be used for common acute conditions, for instance, mastitis.\u003csup\u003e\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e,\u003cspan citationid=\"CR37\" class=\"CitationRef\"\u003e37\u003c/span\u003e\u003c/sup\u003e Although it is not the recommended antibiotic for mastitis,\u003csup\u003e\u003cspan additionalcitationids=\"CR39\" citationid=\"CR38\" class=\"CitationRef\"\u003e38\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR40\" class=\"CitationRef\"\u003e40\u003c/span\u003e\u003c/sup\u003e amoxicillin was the most widely used, which is safe to treat other common infections during lactation, such as respiratory infections.\u003csup\u003e\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e\u003c/sup\u003e Other frequent antibiotic in our analysis included fosfomycin, which is indicated for urinary tract infections, and it is reported to be safe both during pregnancy and breastfeeding.\u003csup\u003e\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e,\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e\u003c/sup\u003e Analgesics, mainly paracetamol, and NSAID, mainly ibuprofen, were also commonly used and increased from month 6 to 12, probably related to the decrease of breast milk feedings over time. Both ibuprofen and paracetamol are safe analgesic during breastfeeding.\u003csup\u003e\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e\u003c/sup\u003e Also some drugs for prevalent respiratory conditions were frequently used, such as inhalers or antihistamines, most being compatible with breastfeeding.\u003csup\u003e\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e,\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e\u003cp\u003eInformation on drug exposure during pregnancy from different populations is available in the literature, whereas there is not as much information concerning breastfeeding. Palmsten et al. is one of the most recent studies reporting drug exposure in lactating mothers at 2, 4 and 6 months after birth, including 4,198 infants receiving breastmilk and born from May 2018 to June 2019, collected during the routine child health care visits. The most common drug exposures included progestin contraceptives (19.1%), or selective-serotonin reuptake inhibitors (SSRI) antidepressants (8.8%). As in our study, they also reported some antibacterials and NSAID among the most frequent ones.\u003csup\u003e\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e\u003cp\u003eA birth cohort in Brazil included 3,988 lactating women in 2015 and studied drug exposure at delivery and after 3 and 12 months while breastfeeding. They reported central nervous system medications as the most frequently used (29%), and others similar to those found in our study, such as paracetamol or ferrous sulphate.\u003csup\u003e\u003cspan citationid=\"CR41\" class=\"CitationRef\"\u003e41\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e\u003cp\u003eMalm et al. conducted a register-based study in Finland in 1999 in pregnant and lactating population, reporting decline throughout the pregnancy period and increase again during lactation for: systemic antimycotics, NSAID, antipsychotics, anxiolytics, hypnotics, sedatives, antidepressants and antihistamines. Antiepileptics use remained stable throughout pregnancy and lactation.\u003csup\u003e\u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e\u003cp\u003eDe Waard et al. conducted a survey in 292 Dutch women to study prevalence of drug use in pregnancy and lactation. Frequent medications included analgesics, vitamins, iron and laxatives.\u003csup\u003e\u003cspan citationid=\"CR42\" class=\"CitationRef\"\u003e42\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e\u003cp\u003eCampbell et al. extracted data from calls to a teratogen information service in Utah, USA (MotherToBaby Utah), during 2009\u0026ndash;2012. They identified 46,031 drug exposures, concerning breastfeeding 34.2% of them, but the drugs reported did not distinguish between pregnancy or lactation exposures.\u003csup\u003e\u003cspan citationid=\"CR43\" class=\"CitationRef\"\u003e43\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e\u003cp\u003eSome studies focused on antidepressants during pregnancy or at delivery. The Australian cohort of Legget et al. included 32,662 women delivering in 2001\u0026ndash;2008 and obtained data from hospital EHR for those breastfeeding at discharge after birth. \u003csup\u003e\u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e\u003c/sup\u003e They studied exposure to antidepressants, reported in 1.8% of the cohort, compared with unexposed with and without psychiatric illness.\u003csup\u003e\u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e\u003c/sup\u003e Gorman et al. also studied SSRI exposure at the time of delivery for 446 mothers in California and found that those exposed were significantly less likely to initiate breastfeeding.\u003csup\u003e\u003cspan citationid=\"CR44\" class=\"CitationRef\"\u003e44\u003c/span\u003e\u003c/sup\u003e Also Jordan et al. found that pregnant women exposed to antidepressants breastfed less frequently than non-exposed.\u003csup\u003e\u003cspan citationid=\"CR45\" class=\"CitationRef\"\u003e45\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e\u003cp\u003eIn summary, apart from Palmsten et al. and Lutz et al., few cohort studies have analyzed drug exposure during lactation. Both studies reported mothers\u0026rsquo; drug use at different time-cuts during the lactation period, finding similar frequent drugs to those reported in our study.\u003c/p\u003e\u003cp\u003eIn our setting, breastfeeding is routinely recorded in the infants\u0026rsquo; EHR, making it necessary to use mother-infant linked information to study mothers\u0026rsquo; drug exposure. The potential limitations of using this approach should be considered. The first limitation could be the misclassification of lactation status, which is collected during the routine visits during childhood.\u003csup\u003e\u003cspan citationid=\"CR21\" class=\"CitationRef\"\u003e21\u003c/span\u003e\u003c/sup\u003e Thus, a second limitation in our data source could be the inability to distinguish between exclusive breastfeeding and mixed feeding (breast milk and other food) in the lactation registries. A third limitation is caused by the information available on the drug dispensing registries in our database, which might have errors incurring in a potential misclassification of start and end of exposure. Another limitation is the potential underreporting of drug exposure due to lack of information on over the counter or non-reimbursed drugs, such as analgesics, antacids, laxatives or supplements. We cannot estimate the medication used by those mothers whose EHR have not been linked to their infants either, also resulting in lower prevalence estimates.\u003c/p\u003e\u003cp\u003eDespite these limitations, studies conducted with EHR have several strengths which can help to identify commonly used medications during lactation and prioritize research on their safety, such as the mother-infant linked information, long follow-up and thorough registries including valuable information.\u003c/p\u003e\u003cp\u003eSome of the frequently used medications observed in our study have insufficient or inadequate data available regarding the effects on lactating infants, such as SSRI, certain proton-pump inhibitors, or metamizole.\u003csup\u003e\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e\u003c/sup\u003e Those drugs could be prioritized in future safety studies in lactating mothers. More studies covering the limitations mentioned are still needed, in order to analyze the safety of using drugs during lactation both in the mothers and the infants\u0026rsquo; health. Also, more tools to help decision making for prescribers are necessary for the purpose of selecting safe and lactation-compatible drugs.\u003c/p\u003e"},{"header":"Conclusions","content":"\u003cp\u003eThe number of lactating and drug-exposed mothers decreased over time. Iron and supplements were the most used drugs, mainly during the first two months, probably due to continuation since pregnancy or post-partum anemia. Analgesics and penicillins were also frequent, which might be used for common acute conditions. Despite the limitations, our study conducted with EHR add evidence which may help to identify commonly used drugs during lactation and prioritize further studies on their safety.\u003c/p\u003e"},{"header":"Abbreviations","content":"\u003cp\u003eASSIR:\u0026nbsp;Sexual and reproductive healthcare. ATC:\u0026nbsp;Anatomical Therapeutic Chemical CLASSIFICATION. ECAP: electronic health records in Catalonia. EHR: Electronic Health Records. FDA: United States Food and Drug Administration. ICD-10-CM:\u0026nbsp;International Classification of Diseases, 10\u003csup\u003eth\u003c/sup\u003e revision, Clinical Modification. MEDEA: socioeconomic index, \u003cem\u003eMortalidad en \u0026aacute;reas peque\u0026ntilde;as Espa\u0026ntilde;olas y Desigualdades socio-Econ\u0026oacute;micas y Ambientales\u003c/em\u003e. NSAID: non-steroidal anti-inflammatory drug. PREFASEG: Safe Pharmacological Prescription. SIDIAP: Information System for Research in Primary Care. SSRI: selective-serotonin reuptake inhibitors.\u003c/p\u003e"},{"header":"Declarations","content":"\u003cp\u003e\u003cstrong\u003eEthics approval and consent to participate\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe study protocol was approved by the Research Ethics Committee of IDIAPJGol (January 2023, project number 22/102-P).\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eThis is a database research study which has been conducted according to the guidelines of the Declaration of Helsinki (Helsinki, Finland 2024) and does not require consent from the people included to participate.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eThe need for consent was waived by the Research Ethics Committee of IDIAPJGol as it is deemed unnecessary according to European legislation (Regulation [EU] 2016/679) and Spanish legislation (Ley Org\u0026aacute;nica 3/2018, dated 6 December 2018, de Protecci\u0026oacute;n de Datos Personales y garant\u0026iacute;a de los derechos digitales).\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eConsent for publication\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eNot applicable, as the study did not require consent from people included to participate either.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAvailability of data and materials\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe datasets generated and/or analysed during the current study are not publicly available due to patient privacy and data protection concerns, but they are available from the corresponding author on reasonable request. All data generated or analysed during this study are included in this published article and its supplementary information files.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompeting interests\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe authors have no relevant financial or non-financial interests to disclose.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFunding\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThis study received funding from the Health Department of the Generalitat de Catalunya, in the 2021 call for the \u0026ldquo;Strategic Plan for Research and Innovation in Health (PERIS) 2022-2024, Research Projects in Primary Care\u0026rdquo;, expedient number SLT021/21/000068.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAuthors\u0026apos; contributions\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eConceptualization: MGS, AGL, RM, CV. Data acquisition: MGS, RM. Data curation: GAR, ACH. Formal analysis: GAR. Funding acquisition: MGS, AGL, MLV, RM, CV. Investigation: all authors. Methodology: all authors. Project administration: MGS, CV. Software: GAR, ACH. Resources: all authors. Supervision: MGS, ACH, RM. Validation: all authors. Visualization: GAR, ACH. Writing \u0026ndash; original draft: MGS. Writing \u0026ndash; review and editing: all authors.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAcknowledgements\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe authors want to thank SIDIAP team for their work in maintaining the database and for their help in the data acquisition.\u0026nbsp;\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\n\u003cli\u003eCHMP. EMEA/CHMP/313666/2005 - Guideline on the Exposure to Medicinal Products During Pregnancy: Need for Post-Authorisation Data. European Medicines Agency. 2005;(November):21. \u003c/li\u003e\n\u003cli\u003eMcGregor AJ, Hasnain M, Sandberg K, Morrison MF, Berlin M, Trott J. How to study the impact of sex and gender in medical research: A review of resources. Biol Sex Differ [Internet]. 2016;7(Suppl 1). Available from: http://dx.doi.org/10.1186/s13293-016-0099-1\u003c/li\u003e\n\u003cli\u003eMauvais-Jarvis F, Bairey Merz N, Barnes PJ, Brinton RD, Carrero JJ, DeMeo DL, et al. Sex and gender: modifiers of health, disease, and medicine. The Lancet [Internet]. 2020;396(10250):565\u0026ndash;82. Available from: http://dx.doi.org/10.1016/S0140-6736(20)31561-0\u003c/li\u003e\n\u003cli\u003eBriggs G, Freeman R, Yaffe S. Drugs in pregnancy and lactation: a reference and neonatal risk. 10th ed. Wolters Kluwer Health, editor. Philadelphia, USA; 2015. \u003c/li\u003e\n\u003cli\u003ePernia S, Demaagd G. The new pregnancy and lactation labeling rule. P and T. 2016;41(11):713\u0026ndash;5. \u003c/li\u003e\n\u003cli\u003eFDA. Content and format of labeling for human prescription drug and biological products; requirements for pregnancy and lactation labeling. Final rule. Fed Regist. 2014;79(233):72063\u0026ndash;103. \u003c/li\u003e\n\u003cli\u003eEuropean Medicines Agency. Guideline on good pharmacovigilance practices (GVP) - Product- or Population-Specific Considerations III: Pregnant and breastfeeding women [Internet]. 2019 Dec [cited 2025 Feb 3]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-good-pharmacovigilance-practices-product-population-specific-considerations-iii_en.pdf\u003c/li\u003e\n\u003cli\u003eMcClatchey AK, Shield A, Cheong LH, Ferguson SL, Cooper GM, Kyle GJ. Why does the need for medication become a barrier to breastfeeding? A narrative review. Women and Birth. 2018 Oct 1;31(5):362\u0026ndash;6. \u003c/li\u003e\n\u003cli\u003eParicio-Talayero JM, Mena-Tudela D, Cervera-Gasch \u0026Aacute;, Gonz\u0026aacute;lez-Chord\u0026aacute; VM, Paricio-Burtin Y, S\u0026aacute;nchez-Palomares M, et al. Is it compatible with breastfeeding? www.e-lactancia.org: Analysis of visits, user profile and most visited products. Int J Med Inform. 2020 Sep 1;141:104199. \u003c/li\u003e\n\u003cli\u003ee-lactancia.org. APILAM: Asociaci\u0026oacute;n para la promoci\u0026oacute;n e investigaci\u0026oacute;n cient\u0026iacute;fica y cultural de la lactancia materna [Internet]. actualizado 03 feb 2025. 2002 [cited 2025 Feb 4]. Available from: https://e-lactancia.org\u003c/li\u003e\n\u003cli\u003eECAP blog. ECAP; Estaci\u0026oacute; cl\u0026iacute;nica d\u0026rsquo;atenci\u0026oacute; prim\u0026agrave;ria [Internet]. Available from: https://ecapics.wordpress.com/about/\u003c/li\u003e\n\u003cli\u003eCatal\u0026aacute;n A, Borrell F, Pons \u0026Agrave;, Amado E, Baena JM, Morales V. Seguridad del paciente en atenci\u0026oacute;n primaria: proyecto PREFASEG (PREscripci\u0026oacute;n FArmacol\u0026oacute;gica SEGura). Med Clin (Barc). 2014 Jul 1;143(SUPPL. 1):32\u0026ndash;5. \u003c/li\u003e\n\u003cli\u003eMohamed HH, Ehresmann K, Seburg EM, Vazquez‐Benitez G, Demerath EW, Fields DA, et al. Characterisation and validation of lactation information from structured electronic health records for use in pharmacoepidemiological studies. Paediatr Perinat Epidemiol [Internet]. 2024 Aug 17 [cited 2024 Sep 2];38(6):505\u0026ndash;14. Available from: https://onlinelibrary.wiley.com/doi/10.1111/ppe.13051\u003c/li\u003e\n\u003cli\u003eThurin NH, Pajouheshnia R, Roberto G, Dodd C, Hyeraci G, Bartolini C, et al. From Inception to ConcePTION: Genesis of a Network to Support Better Monitoring and Communication of Medication Safety During Pregnancy and Breastfeeding. Clin Pharmacol Ther [Internet]. 2022 Jan 26;111(1):321\u0026ndash;31. Available from: https://onlinelibrary.wiley.com/doi/10.1002/cpt.2476\u003c/li\u003e\n\u003cli\u003ePalmsten K, Vazquez-Benitez G, JaKa MM, Bandoli G, Ahrens KA, Kharbanda EO. The most common medications dispensed to lactating persons: An electronic health record-based approach. Pharmacoepidemiol Drug Saf. 2023 Oct 1;32(10):1113\u0026ndash;20. \u003c/li\u003e\n\u003cli\u003eLeggett C, Costi L, Morrison JL, Clifton VL, Grzeskowiak LE. Antidepressant Use in Late Gestation and Breastfeeding Rates at Discharge from Hospital. Journal of Human Lactation. 2017 Nov 1;33(4):701\u0026ndash;9. \u003c/li\u003e\n\u003cli\u003eMalm H, Martikainen J, Klaukka T, Neuvonen PJ. Prescription drugs during pregnancy and lactation - A Finnish register-based study. Eur J Clin Pharmacol. 2003 Jun 1;59(2):127\u0026ndash;33. \u003c/li\u003e\n\u003cli\u003eSIDIAP. SIDIAP. Information system for research in Primary Care [Internet]. SIDIAP. 2023. Available from: http://www.sidiap.org/index.php/en\u003c/li\u003e\n\u003cli\u003eRecalde M, Rodr\u0026iacute;guez C, Burn E, Far M, Garc\u0026iacute;a D, Carrere-Molina J, et al. Data Resource Profile: The Information System for Research in Primary Care (SIDIAP). Int J Epidemiol [Internet]. 2022 Apr 13;1\u0026ndash;13. Available from: https://academic.oup.com/ije/advance-article/doi/10.1093/ije/dyac068/6567646\u003c/li\u003e\n\u003cli\u003eDepartament de Salut G de C. CIM-10-MC/SCP [Internet]. Available from: https://catsalut.gencat.cat/ca/proveidors-professionals/registres-catalegs/catalegs/diagnostics-procediments/cim-10-mc-scp/\u003c/li\u003e\n\u003cli\u003eDepartament de Salut. Generalitat de Catalunya. Protocol d\u0026rsquo;activitats preventives i de promoci\u0026oacute; de la salut a l\u0026rsquo;edat pedi\u0026agrave;trica: cr\u0026eacute;ixer amb salut [Internet]. 2025 [cited 2025 Feb 11]. Available from: https://hdl.handle.net/11351/1197.2\u003c/li\u003e\n\u003cli\u003eWHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD Index 2025 [Internet]. 2025. Available from: https://www.whocc.no/atc_ddd_index/\u003c/li\u003e\n\u003cli\u003eSegundo E, Far M, Rodr\u0026iacute;guez-Casado CI, Elorza JM, Carrere-Molina J, Mallol-Parera R, et al. A mother-child data linkage approach using data from the information system for the development of research in primary care (SIDIAP) in Catalonia. J Biomed Inform. 2024 Nov 1;159. \u003c/li\u003e\n\u003cli\u003eDom\u0026iacute;nguez-Berj\u0026oacute;n M, Borrell C, Cano-Serral G, Esnaola S, Nolasco A, Pasarin M, et al. Construcci\u0026oacute;n de un \u0026iacute;ndice de privaci\u0026oacute;n a partir de datos censales en grandes ciudades espa\u0026ntilde;olas (Proyecto MEDEA). Gac Sanit. 2008;22(3):179\u0026ndash;87. \u003c/li\u003e\n\u003cli\u003eWorld Health Organization W. Breastfeeding recommendations, WHO [Internet]. WHO. 2025 [cited 2025 Feb 11]. Available from: https://www.who.int/health-topics/breastfeeding#tab=tab_1\u003c/li\u003e\n\u003cli\u003eSeguridad Social. Ministerio de Inclusi\u0026oacute;n SS y M. Rest periods in relation to the Workers\u0026rsquo; Statute (ET), birth and child care [Internet]. Art. 48.4, 5 and 6 of the Workers\u0026rsquo; Statute (ET). 2025 [cited 2025 Feb 11]. Available from: https://www.seg-social.es/wps/portal/wss/internet/Trabajadores/PrestacionesPensionesTrabajadores/6b96a085-4dc0-47af-b2cb-97e00716791e/0b5879ed-1156-4676-b38c-7229dcba9c49?changeLanguage=en\u003c/li\u003e\n\u003cli\u003eMart\u0026iacute;n-Ramos S, Dom\u0026iacute;nguez-Aurrecoechea B, Garc\u0026iacute;a Vera C, Lorente Garc\u0026iacute;a Mauri\u0026ntilde;o AM, S\u0026aacute;nchez Almeida E, Sol\u0026iacute;s-S\u0026aacute;nchez G. Lactancia materna en Espa\u0026ntilde;a y factores relacionados con su instauraci\u0026oacute;n y mantenimiento: estudio LAyDI (PAPenRed). Aten Primaria. 2024 Jan 1;56(1):102772. \u003c/li\u003e\n\u003cli\u003eVila-Candel R, Soriano-Vidal FJ, Franco-Antonio C, Garcia-Algar O, Andreu-Fernandez V, Mena-Tudela D. Factors Influencing Duration of Breastfeeding: Insights from a Prospective Study of Maternal Health Literacy and Obstetric Practices. Nutrients [Internet]. 2024 Mar 1 [cited 2025 Feb 11];16(5):690. Available from: https://www.mdpi.com/2072-6643/16/5/690/htm\u003c/li\u003e\n\u003cli\u003eOrtega-Ram\u0026iacute;rez AD, Maneschy IR, Miguel-Berges ML, Pastor-Villaescusa B, Leis R, Babio N, et al. Early feeding practices and eating behaviour in preschool children: The CORALS cohort. Matern Child Nutr. 2024 Oct 1; \u003c/li\u003e\n\u003cli\u003eMena-Tudela D, Soriano-Vidal FJ, Vila-Candel R, Quesada JA, Mart\u0026iacute;nez-Porcar C, Martin-Moreno JM. Is Early Initiation of Maternal Lactation a Significant Determinant for Continuing Exclusive Breastfeeding up to 6 Months? International Journal of Environmental Research and Public Health 2023, Vol 20, Page 3184 [Internet]. 2023 Feb 11 [cited 2024 Dec 10];20(4):3184. Available from: https://www.mdpi.com/1660-4601/20/4/3184/htm\u003c/li\u003e\n\u003cli\u003eMart\u0026iacute;n-Ramos S, Dom\u0026iacute;nguez-Aurrecoechea B, Garc\u0026iacute;a Vera C, Lorente Garc\u0026iacute;a Mauri\u0026ntilde;o AM, S\u0026aacute;nchez Almeida E, Sol\u0026iacute;s-S\u0026aacute;nchez G. Lactancia materna en Espa\u0026ntilde;a y factores relacionados con su instauraci\u0026oacute;n y mantenimiento: estudio LAyDI (PAPenRed). Aten Primaria [Internet]. 2024 Jan 1 [cited 2025 May 28];56(1):102772. Available from: https://www.sciencedirect.com/science/article/pii/S0212656723002056?via%3Dihub\u003c/li\u003e\n\u003cli\u003eMart\u0026iacute;n-Ramos S, Dom\u0026iacute;nguez-Aurrecoechea B, S\u0026aacute;nchez Echenique M, Garcia P\u0026eacute;rez R, Bonet Garrosa A, Sol\u0026iacute;s-S\u0026aacute;nchez G. Breastfeeding duration and nutritional status of infants and toddlers in Spain. LAyDI study (PAPenRed). Anales de Pediatr\u0026iacute;a (English Edition). 2024 Sep 1;101(3):172\u0026ndash;82. \u003c/li\u003e\n\u003cli\u003eInfante-Torres N, Molina-Alarc\u0026oacute;n M, Rubio-\u0026Aacute;lvarez A, Rodr\u0026iacute;guez-Almagro J, Hern\u0026aacute;ndez-Mart\u0026iacute;nez A. Relationship between duration of second stage of labour and postpartum anaemia. Women and Birth. 2018 Oct 1;31(5):e318\u0026ndash;24. \u003c/li\u003e\n\u003cli\u003eRubio-\u0026Aacute;lvarez A, Molina-Alarc\u0026oacute;n M, Hern\u0026aacute;ndez-Mart\u0026iacute;nez A. Incidence of postpartum anaemia and risk factors associated with vaginal birth. Women and Birth. 2018 Jun 1;31(3):158\u0026ndash;65. \u003c/li\u003e\n\u003cli\u003eMedina Garrido C, Le\u0026oacute;n J, Roman\u0026iacute; Vidal A. Maternal anaemia after delivery: prevalence and risk factors. J Obstet Gynaecol (Lahore) [Internet]. 2018 Jan 2 [cited 2025 Feb 11];38(1):55\u0026ndash;9. Available from: https://www.tandfonline.com/doi/abs/10.1080/01443615.2017.1328669\u003c/li\u003e\n\u003cli\u003eUrquizu I Brichs X, Rodriguez Carballeira M, Garc\u0026iacute;a Fern\u0026aacute;ndez A, Perez E, Nol P. Anaemia in pregnancy and in the immediate postpartum period. Prevalence and risk factors in pregnancy and childbirth. Vol. 146, Med Clin (Barc). 2016. \u003c/li\u003e\n\u003cli\u003eMary ST, Antonio DCC, Stephane D, Michael A, Francesca G, Claude B, et al. Subclinical Mastitis in a European Multicenter Cohort: Prevalence, Impact on Human Milk (HM) Composition, and Association with Infant HM Intake and Growth. Nutrients 2020, Vol 12, Page 105 [Internet]. 2019 Dec 30 [cited 2025 Feb 11];12(1):105. Available from: https://www.mdpi.com/2072-6643/12/1/105/htm\u003c/li\u003e\n\u003cli\u003eAmir LH. ABM Clinical Protocol #4: Mastitis, Revised March 2014. Breastfeeding Medicine [Internet]. 2014 Jun [cited 2025 Feb 4];9(5):239\u0026ndash;43. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4048576/pdf/bfm.2014.9984.pdf\u003c/li\u003e\n\u003cli\u003eEsp\u0026iacute;nola-Docio B, Costa-Romero M, D\u0026iacute;az-G\u0026oacute;mez M, Paricio-Talayero JM. Mastitis. Puesta al d\u0026iacute;a. Arch Argent Pediatr. 2016 Dec 1;114(6). \u003c/li\u003e\n\u003cli\u003eParicio Talayero JM. Diagn\u0026oacute;stico y manejo de la mastitis en la madre lactante. Actualizaci\u0026oacute;n. In: IX Congreso Espa\u0026ntilde;ol de Lactancia Materna [Internet]. 2017 [cited 2025 Feb 4]. Available from: https://www.e-lactancia.org/media/papers/Mastitis_Texto-CongrLM_Zar-Paricio.pdf\u003c/li\u003e\n\u003cli\u003eLutz BH, Bassani DG, Miranda VIA, Silveira MPT, Mengue SS, Dal Pizzol T da S, et al. Use of medications by breastfeeding women in the 2015 pelotas (Brazil) birth cohort study. Int J Environ Res Public Health. 2020 Jan 2;17(2). \u003c/li\u003e\n\u003cli\u003ede Waard M, Blomjous BS, Hol MLF, Sie SD, Corpeleijn WE, van Goudoever J (Hans) B, et al. Medication Use During Pregnancy and Lactation in a Dutch Population. Journal of Human Lactation [Internet]. 2019 Feb 3;35(1):154\u0026ndash;64. Available from: https://journals.sagepub.com/doi/10.1177/0890334418775630\u003c/li\u003e\n\u003cli\u003eCampbell SC, Kast TT, Kamyar M, Robertson J, Sherwin CM. Calls to a teratogen information service regarding potential exposures in pregnancy and breastfeeding. BMC Pharmacol Toxicol [Internet]. 2016 Jul 23 [cited 2025 Feb 12];17(1):1\u0026ndash;6. Available from: https://bmcpharmacoltoxicol.biomedcentral.com/articles/10.1186/s40360-016-0076-7\u003c/li\u003e\n\u003cli\u003eGorman JR, Kao K, Chambers CD. Breastfeeding among women exposed to antidepressants during pregnancy. Journal of Human Lactation [Internet]. 2012 May [cited 2025 Feb 12];28(2):181\u0026ndash;8. Available from: http://jhl.sagepub.com\u003c/li\u003e\n\u003cli\u003eJordan S, Davies GI, Thayer DS, Tucker D, Humphreys I. Antidepressant prescriptions, discontinuation, depression and perinatal outcomes, including breastfeeding: A population cohort analysis. PLoS One. 2019 Nov 1;14(11). \u003c/li\u003e\n\u003c/ol\u003e"},{"header":"Tables","content":"\u003ch3\u003eTable 1. Baseline sociodemographic and clinical characteristics of mothers linked to infants receiving breast milk after birth\u003c/h3\u003e\n\u003cp\u003e\u003cimg src=\"data:image/png;base64,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\" width=\"620\" height=\"593\"\u003e\u003c/p\u003e\n\u003cp\u003eSD: standard deviation. IQR: interquartile range MEDEA: socioeconomic index of one rural category and five urban categories/quintiles.\u003c/p\u003e\n\u003ch3\u003eTable 2. Drug exposure in mothers during the 12 after birth.\u003c/h3\u003e\n\u003ctable border=\"1\" cellspacing=\"0\" cellpadding=\"0\" width=\"604\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"3\" style=\"width: 100%;\"\u003e\n \u003cp\u003e\u003cstrong\u003eMother exposed to drugs during all the study period\u003c/strong\u003e\u003c/p\u003e\n \u003cp\u003e\u003cstrong\u003eN= 96,094\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 42.2185%;\"\u003e\n \u003cp\u003e\u003cstrong\u003eDrugs\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 21.8543%;\"\u003e\n \u003cp\u003e\u003cstrong\u003eTotal exposure over the 12 months, n (%)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 35.9272%;\"\u003e\n \u003cp\u003e\u003cstrong\u003eMore frequent drug, n (%*)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 42.2185%;\"\u003e\n \u003cp\u003eOral iron\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 21.8543%;\"\u003e\n \u003cp\u003e44,102 (25.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 35.9272%;\"\u003e\n \u003cp\u003eFerrous sulfate, 31,406 (71.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 42.2185%;\"\u003e\n \u003cp\u003eAnalgesics\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 21.8543%;\"\u003e\n \u003cp\u003e31,102 (17.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 35.9272%;\"\u003e\n \u003cp\u003eParacetamol, 28,068 (90.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 42.2185%;\"\u003e\n \u003cp\u003eFolic acid\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 21.8543%;\"\u003e\n \u003cp\u003e27,396 (15.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 35.9272%;\"\u003e\n \u003cp\u003eFolic acid, 27,396 (100.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 42.2185%;\"\u003e\n \u003cp\u003eBeta-lactam antibacterials\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 21.8543%;\"\u003e\n \u003cp\u003e25,536 (14.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 35.9272%;\"\u003e\n \u003cp\u003eAmoxicillin, 22,984 (90.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 42.2185%;\"\u003e\n \u003cp\u003eNSAID\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 21.8543%;\"\u003e\n \u003cp\u003e24,114 (13.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 35.9272%;\"\u003e\n \u003cp\u003eIbuprofen, 18,224 (75.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 42.2185%;\"\u003e\n \u003cp\u003eVitamin B12\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 21.8543%;\"\u003e\n \u003cp\u003e22,604 (12.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 35.9272%;\"\u003e\n \u003cp\u003eCyanocobalamin, 22,604 (100.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 42.2185%;\"\u003e\n \u003cp\u003eGynecological anti-infectives/antiseptics\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 21.8543%;\"\u003e\n \u003cp\u003e6,473 (3.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 35.9272%;\"\u003e\n \u003cp\u003eClotrimazole (topical), 3,784 (58.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 42.2185%;\"\u003e\n \u003cp\u003eOther antibacterials\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 21.8543%;\"\u003e\n \u003cp\u003e5,975 (3.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 35.9272%;\"\u003e\n \u003cp\u003eFosfomycin, 5,340 (89.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 42.2185%;\"\u003e\n \u003cp\u003eSystemic antihistamines\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 21.8543%;\"\u003e\n \u003cp\u003e5,323 (3.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 35.9272%;\"\u003e\n \u003cp\u003eCetirizine, 1,855 (34.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 42.2185%;\"\u003e\n \u003cp\u003eHeparins\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 21.8543%;\"\u003e\n \u003cp\u003e5,107 (2.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 35.9272%;\"\u003e\n \u003cp\u003eEnoxaparin, 3,574 (70.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 42.2185%;\"\u003e\n \u003cp\u003eThyroid hormones\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 21.8543%;\"\u003e\n \u003cp\u003e3,723 (2.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 35.9272%;\"\u003e\n \u003cp\u003eLevothyroxine, 3,722 (100.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 42.2185%;\"\u003e\n \u003cp\u003eBeta-2-adrenoceptor agonists, inhaled\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 21.8543%;\"\u003e\n \u003cp\u003e3,172 (1.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 35.9272%;\"\u003e\n \u003cp\u003eSalbutamol, 2,176 (68.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 42.2185%;\"\u003e\n \u003cp\u003eProton pump inhibitors\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 21.8543%;\"\u003e\n \u003cp\u003e2,902 (1.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 35.9272%;\"\u003e\n \u003cp\u003eOmeprazole, 2,716 (93.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 42.2185%;\"\u003e\n \u003cp\u003eMacrolides\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 21.8543%;\"\u003e\n \u003cp\u003e2,295 (1.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 35.9272%;\"\u003e\n \u003cp\u003eAzithromycin, 1,062 (46.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 42.2185%;\"\u003e\n \u003cp\u003eGlucocorticoids inhaled\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 21.8543%;\"\u003e\n \u003cp\u003e2,136 (1.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 35.9272%;\"\u003e\n \u003cp\u003eBudesonide, 1,548 (72.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 42.2185%;\"\u003e\n \u003cp\u003eAnxiolytics, hypnotics and sedatives\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 21.8543%;\"\u003e\n \u003cp\u003e1,880 (1.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 35.9272%;\"\u003e\n \u003cp\u003eDiazepam, 683 (36.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 42.2185%;\"\u003e\n \u003cp\u003eH2 \u0026ndash; receptor antagonists\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 21.8543%;\"\u003e\n \u003cp\u003e1,804 (1.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 35.9272%;\"\u003e\n \u003cp\u003eRanitidine, 1,766 (97.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 42.2185%;\"\u003e\n \u003cp\u003eOther systemic hormonal preparations, excluding sex hormones and insulins\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 21.8543%;\"\u003e\n \u003cp\u003e1,656 (0.94)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 35.9272%;\"\u003e\n \u003cp\u003ePrednisone, 1,117 (67.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 42.2185%;\"\u003e\n \u003cp\u003eSSRI antidepressants\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 21.8543%;\"\u003e\n \u003cp\u003e1,645 (0.93)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 35.9272%;\"\u003e\n \u003cp\u003eSertraline, 457 (27.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 42.2185%;\"\u003e\n \u003cp\u003eLaxatives\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 21.8543%;\"\u003e\n \u003cp\u003e1,632 (0.93)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 35.9272%;\"\u003e\n \u003cp\u003eIspaghula, 1,041 (63.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 42.2185%;\"\u003e\n \u003cp\u003eBeta-blockers\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 21.8543%;\"\u003e\n \u003cp\u003e1,586 (0.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 35.9272%;\"\u003e\n \u003cp\u003eLabetalol, 1,409 (88.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 42.2185%;\"\u003e\n \u003cp\u003eOther beta-lactam antibacterials\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 21.8543%;\"\u003e\n \u003cp\u003e1,532 (0.87)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 35.9272%;\"\u003e\n \u003cp\u003eCefuroxime, 971 (63.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 42.2185%;\"\u003e\n \u003cp\u003eQuinolones\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 21.8543%;\"\u003e\n \u003cp\u003e1,455 (0.83)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 35.9272%;\"\u003e\n \u003cp\u003eCiprofloxacin, 1,088 (74.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 42.2185%;\"\u003e\n \u003cp\u003eVitamins\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 21.8543%;\"\u003e\n \u003cp\u003e1,162 (0.66)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 35.9272%;\"\u003e\n \u003cp\u003eCholecalciferol, 1,041 (89.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e*% calculated on the overall exposure of the group.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eNSAID: non-steroidal anti-inflammatory drugs. SSRI: selective-serotonin reuptake inhibitors\u003c/p\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":false,"highlight":"","institution":"","isAcceptedByJournal":true,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"international-breastfeeding-journal","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"ibfj","sideBox":"Learn more about [International Breastfeeding Journal](http://internationalbreastfeedingjournal.biomedcentral.com/)","snPcode":"13006","submissionUrl":"https://submission.nature.com/new-submission/13006/3","title":"International Breastfeeding Journal","twitterHandle":"@BioMedCentral","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"em","reportingPortfolio":"BMC/SO AJ","inReviewEnabled":true,"inReviewRevisionsEnabled":true},"keywords":"Breastfeeding, Lactation, Drug exposure, Electronic Health Records, Mother-child relation, Pharmacoepidemiology, Prevalence","lastPublishedDoi":"10.21203/rs.3.rs-7091470/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-7091470/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003e\u003cb\u003eBackground\u003c/b\u003e\u003c/p\u003e\u003cp\u003eThere is a gap in the knowledge of drug exposure during breastfeeding due to exclusion of lactating individuals from studies. It makes difficult to fully understand the implication of drug use while breastfeeding and potential risks to newborns. Breastfeeding information in the Electronic Health Records (EHR) may help us to increase this evidence. We aimed to describe drug exposure during breastfeeding in mothers of a cohort of mother-infant linked pairs in Catalonia, Spain.\u003c/p\u003e\u003cp\u003e\u003cb\u003eMethods\u003c/b\u003e\u003c/p\u003e\u003cp\u003eWe conducted a descriptive population-based cohort study including mother-infant linked pairs of infants born during 2010\u0026ndash;2022. The data source was the Information System for Research in Primary Care (SIDIAP), including sociodemographic characteristics, comorbidities, prescribed and reimbursed drugs, and lactation registers. Lactation is registered in the infants\u0026rsquo; EHR. We analyzed drug exposure from delivery up to 2, 4, 6 and 12 months afterwards. We described categorical variables by absolute frequency and percentage and continuous variables by mean and standard deviation.\u003c/p\u003e\u003cp\u003e\u003cb\u003eResults\u003c/b\u003e\u003c/p\u003e\u003cp\u003eWe included 176,324 mother-infant pairs with lactation registers during the first year after birth. Breastfed infants decreased during the first year to 64,225 (36.4%). Drug exposure varied from 76,064 (43.1% of the lactating mothers) from delivery up to month 2, to 32,475 (21.9%), 17,396 (17.6%) and 20,433 (31.8%) at up to months 4, 6 and 12, respectively. The most dispensed drugs were iron (25%), folic acid (15.5%) and analgesics (17.8%). Paracetamol was the most frequent analgesic (89.7%), amoxicillin and fosfomycin were the most frequent antibiotics (92.4% and 89.4%), or ibuprofen the most frequent non-steroidal anti-inflammatory drug (75.6%).\u003c/p\u003e\u003cp\u003e\u003cb\u003eConclusions\u003c/b\u003e\u003c/p\u003e\u003cp\u003eThe number of lactating and drug-exposed mothers decreased over time. Iron and supplements were the most used drugs, mainly during the first two months, probably due to continuation since pregnancy or post-partum anemia. Analgesics and penicillins were also frequent, which might be used for common acute conditions. Our main limitation is the potential underreporting of drug exposure due to lack of information on over-the-counter drugs.\u003c/p\u003e\u003cp\u003e\u003cb\u003eTrial registration\u003c/b\u003e\u003c/p\u003e\u003cp\u003e\u0026ldquo;Drug use in pregnant and breastfeeding women. Outcomes in the health of the women and the offspring\u0026rdquo;, EUPAS47450, registered at the HMA-EMA Catalogues of real-world data sources and studies: \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://catalogues.ema.europa.eu/node/3222/administrative-details\u003c/span\u003e\u003cspan address=\"https://catalogues.ema.europa.eu/node/3222/administrative-details\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/p\u003e","manuscriptTitle":"Drug exposure during breastfeeding: a descriptive population- based cohort study with SIDIAP database","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2025-08-27 05:54:32","doi":"10.21203/rs.3.rs-7091470/v1","editorialEvents":[{"type":"communityComments","content":0},{"type":"decision","content":"Revision requested","date":"2025-10-17T13:49:07+00:00","index":"","fulltext":""},{"type":"editorInvitedReview","content":"","date":"2025-10-17T08:15:15+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"293389213213472853867077627273339568168","date":"2025-09-29T07:04:21+00:00","index":"hide","fulltext":""},{"type":"editorInvitedReview","content":"","date":"2025-09-11T09:09:57+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"76975011086668719087003270564959576888","date":"2025-08-21T06:28:44+00:00","index":"hide","fulltext":""},{"type":"reviewersInvited","content":"","date":"2025-08-15T19:10:04+00:00","index":"","fulltext":""},{"type":"editorAssigned","content":"","date":"2025-07-12T18:55:12+00:00","index":"","fulltext":""},{"type":"checksComplete","content":"","date":"2025-07-12T18:54:20+00:00","index":"","fulltext":""},{"type":"submitted","content":"International Breastfeeding Journal","date":"2025-07-10T09:32:06+00:00","index":"","fulltext":""}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"international-breastfeeding-journal","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"ibfj","sideBox":"Learn more about [International Breastfeeding Journal](http://internationalbreastfeedingjournal.biomedcentral.com/)","snPcode":"13006","submissionUrl":"https://submission.nature.com/new-submission/13006/3","title":"International Breastfeeding Journal","twitterHandle":"@BioMedCentral","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"em","reportingPortfolio":"BMC/SO AJ","inReviewEnabled":true,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"82c43b89-f3e0-4e1f-a8d5-bd19e0eb099b","owner":[],"postedDate":"August 27th, 2025","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"published-in-journal","subjectAreas":[],"tags":[],"updatedAt":"2025-12-29T16:03:19+00:00","versionOfRecord":{"articleIdentity":"rs-7091470","link":"https://doi.org/10.1186/s13006-025-00797-3","journal":{"identity":"international-breastfeeding-journal","isVorOnly":false,"title":"International Breastfeeding Journal"},"publishedOn":"2025-12-24 15:58:30","publishedOnDateReadable":"December 24th, 2025"},"versionCreatedAt":"2025-08-27 05:54:32","video":"","vorDoi":"10.1186/s13006-025-00797-3","vorDoiUrl":"https://doi.org/10.1186/s13006-025-00797-3","workflowStages":[]},"version":"v1","identity":"rs-7091470","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-7091470","identity":"rs-7091470","version":["v1"]},"buildId":"8U1c8b4HqxoKbykW_rLl7","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}